Cell Therapy’s Tendoncel, a topical gel for the treatment of severe tendon injuries, has successfully completed its phase II. The optimistic results from the clinical trial add to those of the company’s leading product, released last week. The UK company has finally started to collect strong clinical data to support its approach.
Cell Therapy Limited was created in 2002 by a couple of notorious founders: Sir Martin Evans, Nobel Prize in Physiology, and Ajan Reginald, ex-Global Head of Emerging Technologies at Roche. With such well-recognized parents, the expectations regarding the company were high. However, the achievements took a long time to arrive. The companies succeeded in raising almost one million euros by crowdfunding, but the clinical victories only came very recently.
Last week, the Cardiff-based company presented the data of a positive phase II of Heartcel, the company’s lead candidate indicated for heart failure. Now, Cell Therapy released its results from another successful phase II of Tendoncel, for severe tendon injury repair.
The drug candidate is a regenerative allogeneic gel that incorporates a unique combination of platelet growth factors in a cellulose-derived gel,